Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20342887 | 0.85 | TDP1 (0.62) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL1509290 | 0.82 | HSD17B10 (0.54) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL472112 | 0.81 | TDP1 (1.00) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| Phosphine SCHEMBL28283987 | 0.80 | HSD17B10 (0.52) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| Ammonia Solution, Strong SCHEMBL28268609 | 0.80 | HSD17B10 (0.52) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL9847284 | 0.79 | TDP1 (0.48) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL5183666 | 0.79 | TDP1 (0.48) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL31689533 | 0.79 | TDP1 (0.67) | TDP1TSHRSMN1; SMN2GPR35MAPT | |
| SCHEMBL6786619 | 0.79 | TDP1 (0.48) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 | |
| SCHEMBL18831337 | 0.77 | TDP1 (0.51) | TDP1TSHRSMN1; SMN2HSD17B10GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3088382-B1 | METHOD FOR PRODUCING NITRO COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9561998-B2 | Method for producing nitro compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160318846-A1 | METHOD FOR PRODUCING NITRO COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| EP-3088382-A1 | METHOD FOR PRODUCING NITRO COMPOUND | Sumitomo Chemical Company Limited (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-8263590-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-7964592-B2 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-2287156-A1 | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| EP-1161418-B1 | 1-ACYL-7-NITROINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHOTOCLEAVABLE PRECURSORS | MEDICAL RES COUNCIL (GB) | 2005-12-28 | — | — | EP | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-6765014-B1 | DRUG DELIVERY OF NEUROACTIVE AMINO ACIDS OR METAL CHELATORS | MEDICAL RESEARCH COUNCIL (GB) | 2004-07-20 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | ESSER FRANZ (DE) | 2002-04-04 | — | — | US | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318846-A1 | METHOD FOR PRODUCING NITRO COMPOUND | NOS1, NOS3, NOS2 | TDP1 3246/4885TSHR 1679/4885SMN1; SMN2 2329/4885 |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | TDP1 161/4885TSHR 4416/4885SMN1; SMN2 1572/4885 |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | TDP1 2969/4885TSHR 2606/4885SMN1; SMN2 2033/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | TDP1 2671/4885TSHR 4526/4885SMN1; SMN2 539/4885 |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | DPYD, TYMP, TYMS | TDP1 334/4885TSHR 3527/4885SMN1; SMN2 1651/4885 |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | COL1A1, TPSAB1, TACR1 | TDP1 963/4885TSHR 3011/4885SMN1; SMN2 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.